Predictors of response to bDMARDs and tsDMARDs in psoriatic arthritis: a pilot study on the role of musculoskeletal ultrasound
2024

Predictors of Response to Biologic and Targeted Synthetic Drugs in Psoriatic Arthritis

Sample size: 29 publication Evidence: moderate

Author Information

Author(s): Cozzi Giacomo, Scagnellato Laura, Lorenzin Mariagrazia, Collesei Antonio, Oliviero Francesca, Damasco Amelia, Cosma Chiara, Basso Daniela, Doria Andrea, Ramonda Roberta

Primary Institution: University - Padova University Hospital, Padua, Italy

Hypothesis

This pilot study aimed to identify early predictors of drug retention in patients with clinically active peripheral psoriatic arthritis who initiated or switched to therapy with biologic and targeted synthetic disease-modifying antirheumatic drugs.

Conclusion

Ultrasound imaging of clinically involved joint sites may be a valuable early predictor of therapy response for predicting drug retention at 6 months in patients with psoriatic arthritis.

Supporting Evidence

  • Twenty-nine patients were enrolled, with 22 continuing therapy and 7 discontinuing due to treatment failure.
  • Ultrasound changes were significant in cResponders compared to non-cResponders at various time points.
  • Patients treated with JAK inhibitors showed a faster ultrasound response compared to those treated with TNF inhibitors.

Takeaway

Doctors can use ultrasound to see how well treatment is working for patients with psoriatic arthritis, helping them decide if the patient should keep taking their medicine.

Methodology

Patients were assessed clinically and via ultrasound at baseline and at 1, 3, and 6 months, with outcomes based on ultrasound changes in specific joint scores.

Potential Biases

The ultrasound evaluation was performed by a single sonographer, which may introduce bias.

Limitations

The study had a small sample size and was conducted at a single center, which may limit the generalizability of the findings.

Participant Demographics

The study included 29 patients (14 male, mean age 57.72 years), with a mix of treatment-naïve and those with prior treatment failures.

Statistical Information

P-Value

0.0095

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3389/fmed.2024.1482894

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication